Clinical utility of plasma Amyloid beta biomarker : a multicenter validation study - CUPAB

akamura Akinori0 个研究点目标入组 200 人开始时间: 2020年6月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Cognitively unimpaired individuals;
•1) Written informed consent is obtained.
•2) General condition, visual acuity and hearing ability are sufficiently good to proceed examinations required for this study.
•Mild cognitive impairment, Alzheimer's Disease (AD) , non- AD;
•1) Written informed consent is obtained.The subject's legally acceptable representative must provide the written informed consent form if the subject is unable to provide informed consent.
•2) General condition, visual acuity and hearing ability are sufficiently good to proceed examinations required for this study.
•3) Diagnosed with any of the following diseases at informed consent.
•Mild cognitive impairment
•Alzheimer's Disease (AD)

•Cognitively unimpaired individuals;
•1) GDS (Geriatric depression scale) > 6
•2) Having difficulty to keep supine position due to deformity or dysfunction in the muscle-skeletal system, e.g. problems of the spine or hip joint.
•3) Having contraindications for MRI scans.
•Mild cognitive impairment, AD , non- AD;
•1) GDS > 11
•2) Having difficulty to keep supine position due to deformity or dysfunction in the muscle-skeletal system, e.g. problems of the spine or hip joint.
•3) Having contraindications for MRI scans.

发起方

akamura Akinori